Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-1303 long-term extension in moderate to severe active Crohn's disease
NL-OMON44363Phase 2Active, not recruiting
- Sponsor
- Tanabe Pharma Europe Ltd
- Start
- Feb 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amiselimod in Crohn's disease, sponsored by Tanabe Pharma Europe Ltd. Primary endpoint: Long-term safety and tolerability. Started Feb 2016; status: active, not recruiting.
02
Drugs
amiselimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON44363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44363.